Ginkgo Bioworks Holdings Inc (NYSE:DNA) shares, rose in value on Thursday, May 08, with the stock price up by 6.35% to the previous day’s close as strong demand from buyers drove the stock to $7.87.
Actively observing the price movement in the last trading, the stock closed the session at $7.40. Referring to stock’s 52-week performance, its high was $38.58, and the low was $5.00. On the whole, DNA has fluctuated by 36.63% over the past month.
With the market capitalization of Ginkgo Bioworks Holdings Inc currently standing at about $456.20 million, investors are eagerly awaiting this quarter’s results, scheduled for in June.
Technical indicators serve as essential tools for traders, offering insights into market sentiment and potential price movements. We see that DNA’s technical picture suggests that short-term indicators denote the stock is a Hold on average. However, medium-term indicators have put the stock in the category of 50% Sell while long-term indicators on average have been pointing out that it is a 50% Sell.
The stock’s technical analysis shows that the price of DNA currently trading nearly 3.85% and 9.05% away from the simple moving averages for 20 and 50 days respectively. The Relative Strength Index (RSI, 14) currently indicates a reading of 54.95, while the 7-day volatility ratio is showing 9.86% which for the 30-day chart, stands at 9.95%. Furthermore, Ginkgo Bioworks Holdings Inc (DNA)’s beta value is 1.30, and its average true range (ATR) is 0.73.
A comparison of Ginkgo Bioworks Holdings Inc (DNA) with its peers suggests the former has fared considerably weaker in the market. DNA showed an intraday change of 6.35% in last session, and over the past year, it shrunk by -80.09%%.
Data on historical trading for Ginkgo Bioworks Holdings Inc (NYSE:DNA) indicates that the trading volumes over the past 3 months, they’ve averaged 1.60 million. According to company’s latest data on outstanding shares, there are 43.08 million shares outstanding.
Nearly 31.94% of Ginkgo Bioworks Holdings Inc’s shares belong to company insiders and institutional investors own 60.13% of the company’s shares. The stock has fallen by -19.86% since the beginning of the year, thereby showing the potential of a further growth. This could raise investors’ confidence to be optimistic about the DNA stock heading into the next quarter.
